|
|
|
| home > white papers > Clinical Trials in Russia Orange Paper: 1st Quarter 2014 - Synergy Research Group |
|
|
 WHITE PAPERS |
|
Synergy Research Group
|
|
Clinical Trials in Russia Orange Paper: 1st Quarter 2014
|
|
In summary, Russia remains a very popular geography for local, regional,
and global pharmaceutical companies to conduct clinical trials.
Sponsors mention the following reasons for conducting studies in Russia:
1. Fast patient enrollment due to the centralized medical infrastructure.
2. Nearly 100% patient retention
3. GCP trained and certified Investigative Sites generating high quality data
4.
Low cost: Average per patient cost is 60% to 70% below US and European
prices due to the low cost of Investigators and the high concentration
of patients in therapeutically aligned medical centers
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Biosimilar Drug Development the analytical strategy is keyfactor for your success
Heilbronn/Dortmund March 2019: The generation of analytical data for the comparison between a biosimilar and the originator product is the initial assumption in the development of biosimilars.
Achieving Biosimilarity can be a controversial and complex topic when deciding the right time point and range of analytics.
More info >> |
|
 |
White Papers |
 |
|
Inhaler Adherence: Exploring Key Factors
Aptar Pharma
Aptar Pharma recently hosted an expert panel roundtable on “Inhaler Adherence”. This international scientific forum was held in Paris, France on November 29th 2013. The roundtable was organized to explore and exchange views on the issues which may influence inhaler adherence/ compliance with a particular focus on asthma and C.O.P.D. therapies and their corresponding inhaler devices (MDIs, DPIs).
More info >> |
|
 |
Industry Events |
 |
ChinaBio® Partnering Forum 2019
8-9 May 2019, Shanghai, China
Access a world of opportunities through life science partnering in China.
ChinaBio® Partnering Forum is the premier life science partnering event in China. The conference will be held May 8–9 in Shanghai, attracting biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering.
More info >> |
|
|
|
